FindTrial
Sign In

ABT-530

DRUG7 trials

Sponsors

AbbVie

Conditions

Chronic Hepatitis CCompensated CirrhosisHCVHepatic ImpairmentHepatitis CHepatitis C VirusRenal Impairment

Phase 1

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function
CompletedNCT02296905
AbbVieHepatic Impairment
Start: 2014-10-31End: 2015-09-30Updated: 2015-10-21
Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function
CompletedNCT02442258
AbbVieRenal Impairment
Start: 2015-03-31End: 2015-12-31Updated: 2016-02-22

Phase 2

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
CompletedNCT01995071
AbbVieChronic Hepatitis C, Compensated Cirrhosis, Hepatitis C Virus
Start: 2013-11-30End: 2015-06-30Updated: 2021-07-12
A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection
CompletedNCT02068222
AbbVieChronic Hepatitis C, Hepatitis C Virus
Start: 2014-04-30End: 2015-03-31Updated: 2018-02-22
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
CompletedNCT02243280
AbbVieChronic Hepatitis C, HCV, Hepatitis C Virus
Start: 2014-08-31End: 2016-02-29Updated: 2021-07-13
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
CompletedNCT02243293
AbbVieChronic Hepatitis C, Hepatitis C Virus
Start: 2014-09-19End: 2017-02-23Updated: 2021-07-30
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
CompletedNCT02441283
AbbVieHepatitis C
Start: 2015-06-22End: 2019-10-15Updated: 2020-09-21

Related Papers

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
Infectious Diseases and Therapy2022-02-173 citations
Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
Liver International2019-10-0131 citations
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
Journal of Gastroenterology2019-03-1319 citations
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
Clinical Infectious Diseases2019-01-2336 citations
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
2018-09-1015 citations
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects
Antimicrobial Agents and Chemotherapy2018-02-2222 citations
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
2017-09-22154 citations
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
2017-04-13213 citations
High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
2016-07-2573 citations
Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
Antimicrobial Agents and Chemotherapy2015-12-2959 citations